A 38-year-old woman presents to the emergency department with a 1-week history of worsening fatigue, spontaneous gum bleeding, and easy bruising. Her temperature is 37.8°C (100°F), blood pressure is 110/70 mm Hg, and pulse is 105/min. Physical examination is notable for diffuse petechiae across her chest and extremities, as well as oozing from her intravenous catheter site.
Laboratory studies show:
| Parameter | Result |
|---|---|
| Leukocyte count | |
| Hemoglobin | |
| Platelet count | |
| Prothrombin time (PT) | |
| Activated PTT | |
| Fibrinogen |
A peripheral blood smear demonstrates numerous atypical promyelocytes with multiple needle-like cytoplasmic inclusions.
Arrange the following steps in the most appropriate chronological sequence for the management of this patient's condition.
- 1Administration of all-trans retinoic acid (ATRA)
- 2Bone marrow aspiration and biopsy
- 3Confirmation of the PML-RARA fusion gene
- 4Initiation of comprehensive induction therapy
Answer
The correct sequence of management is: Administration of ATRA, followed by bone marrow aspiration and biopsy, then confirmation of the PML-RARA fusion gene, and finally the initiation of comprehensive induction therapy.
Acute promyelocytic leukemia (APL) is a medical emergency that classically presents with pancytopenia and severe disseminated intravascular coagulation (DIC). The pathognomonic finding is a peripheral smear with atypical promyelocytes containing numerous Auer rods (needle-like inclusions). Because the risk of catastrophic bleeding is extremely high, the standard of care dictates that all-trans retinoic acid (ATRA) must be administered immediately based on clinical and morphological suspicion alone. ATRA induces the differentiation of the leukemic promyelocytes, rapidly reversing the coagulopathy. Once the patient is stabilized and ATRA is initiated, a bone marrow aspiration and biopsy should be performed to secure the diagnosis. From this marrow sample, cytogenetic or molecular studies (such as FISH or RT-PCR) are run to definitively confirm the presence of the t(15;17) translocation and the resulting PML-RARA fusion gene. Only after this definitive confirmation is the comprehensive induction regimen (such as the addition of arsenic trioxide) fully committed to for curative intent.
Step-by-Step Solution
Key Concept
In patients with suspected acute promyelocytic leukemia (APL), all-trans retinoic acid (ATRA) must be administered immediately based on clinical and morphological suspicion alone, prior to waiting for definitive bone marrow biopsy and cytogenetic confirmation.
Alternative Method
While managing the specific leukemia, concurrent supportive care with cryoprecipitate (to keep fibrinogen > 150 mg/dL) and platelets (to keep > 30,000-50,000/µL) should occur simultaneously with ATRA administration.
Estimated Time:1m 30s